摘要:
A monoclonal antibody capable of binding to a glycoprotein antigen having a molecular weight of about 12 x 10⁴ daltons (gp120) present in the envelope of human immunodeficiency virus (HIV) and capable of substantially neutralizing the HIV, or fragments thereof, which has the characteristics of immunoblobulin class IgG, κ, being capable of binding to glycoprotein antigen having a molecular weight of 12 x 10⁴ daltons (gp120) of HTLV-III MN , being capable of recognizing at least one epitope which is present in the region of the amino acid sequence 303 to 325 of gp120 of HTLV-III MN , being capable of binding to the surface of HTLV-III MN viral particles and thereby inhibiting the infection of the viral particles to CD4-positive cells, and being capable of binding to the surface of cells infected with HTLV-IIIMN and thereby inhibiting the syncytium formation induced by interaction between the infected cells and uninfected cells, said monoclonal antibody being useful for the prophylaxis, treatment and diagnosis of AIDS.
摘要:
Described are novel chimeric anti-human immunodeficiency virus (HIV) antibodies which comprise a constant region derived from human antibody and variable region derived from mouse monoclonal antibody, gene fragments coding for the variable region the H and L chain of chimeric anti-HIV antibodies which are effective for expression of chimeric anti-HIV antibodies having an HIV-neutralizing activity, a transformant where such gene fragments are incorporated, chimeric anti-HIV antibodies expressed therefrom and a process for their preparation. The chimeric anti-HIV antibodies of the present invention show anti-HIV neutralizing activity and are useful for the diagnosis, treatment and prevention of acquired immunodeficiency syndrome (AIDS) caused by HIV without side effects such as anaphylactic shock or serum sickness.
摘要:
Described are novel chimeric anti-human immunodeficiency virus (HIV) antibodies which comprise a constant region derived from human antibody and variable region derived from mouse monoclonal antibody, gene fragments coding for the variable region the H and L chain of chimeric anti-HIV antibodies which are effective for expression of chimeric anti-HIV antibodies having an HIV-neutralizing activity, a transformant where such gene fragments are incorporated, chimeric anti-HIV antibodies expressed therefrom and a process for their preparation. The chimeric anti-HIV antibodies of the present invention show anti-HIV neutralizing activity and are useful for the diagnosis, treatment and prevention of acquired immunodeficiency syndrome (AIDS) caused by HIV without side effects such as anaphylactic shock or serum sickness.